ERBB2 and neoplasm: Addressing this uncertainty, the recently published phase 3 DESTINY-Breast0637 trial found a survival benefit in HER2-ultralow patients, i.e., a subset of patients within the IHC category 0 who express faint membrane staining in ≤10% of tumour cells.